Background This pilot study was designed to evaluate the diagnostic value of (68) Ga-PSMA-617 and F-18-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. Methods Thirty patients pathologically diagnosed with ACC were recruited into the cohort. Each patient underwent (68) Ga-PSMA-617 and F-18-FDG PET/CT within 1 week. The number and SUVmax of PET-positive lesions were recorded and compared. Four patients accepted RLT using Lu-177-EB-PSMA-617, in a dosage of approximately 1.85 GBq (50 mCi) per cycle for up to 3 cycles. Results Compared with F-18-FDG, (68) Ga-PSMA-617 revealed more PET-positive extrapulmonary tumors (157 vs. 141, P = 0.016) and higher SUVmax (8.8 +/- 3.6 vs. 6.4 +/- 4.2, P = 0.027). However, (68) Ga-PSMA-617 revealed less PET-positive pulmonary lesions (202 vs. 301, P < 0.001) and lower SUVmax of tumors (3.1 +/- 3.0 vs. 4.2 +/- 3.9, P < 0.001) than F-18-FDG. The combination of (68) Ga-PSMA-617 and F-18-FDG can detect 469 PET-positive lesions, which was superior to each alone (469 vs. 359 vs. 442, P < 0.001). Two patients achieved remarkable response after PSMA RLT, while the other two patients showed reduced tumor uptake of recurrent foci, lung and liver metastases, whereas increased SUVmax of bone metastases. Conclusions (68) Ga-PSMA-617 PET/CT is a valuable imaging modality for the detection of ACC and combining with F-18-FDG PET/CT will achieve a higher detection efficiency. PSMA RLT may be a promising treatment for ACC and is worth of further investigation. .
基金：
Chinese Academy of Medical Science Innovation Fund for Medical Sciences [2021-I2M-1-016]; National Natural Science Foundation of China [81871392]; National University of Singapore [NUHSRO/2020/133/Startup/08]; National Research Foundation, Singapore; National Medical Research Council, Singapore [CG21APR1005]
第一作者机构：[1]Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll,Beijing Key Lab Mol Targete, Dept Nucl Med,State Key Lab Complex Severe & Rare, Beijing 100730, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[3]Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Diagnost Radiol, Singapore 119074, Singapore[4]Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 119074, Singapore[5]Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Chem & Biomol Engn, Singapore 119074, Singapore[6]Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biomed Engn, Singapore 119074, Singapore[7]Natl Univ Singapore, Fac Engn, Singapore 119074, Singapore[8]Natl Univ Singapore, Yong Loo Lin Sch Med, Clin Imaging Res Ctr, Ctr Translat Med, Singapore 117599, Singapore[9]Natl Univ Singapore, NUS Ctr Nanomed, Yong Loo Lin Sch Med, Nanomed Translat Res Program, Singapore 117597, Singapore
推荐引用方式(GB/T 7714)：
Wang Guochang,Zhou Mengjiao,Zang Jie,et al.A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma[J].EJNMMI RESEARCH.2022,12(1):doi:10.1186/s13550-022-00922-x.
APA：
Wang, Guochang,Zhou, Mengjiao,Zang, Jie,Jiang, Yuanyuan,Chen, Xiaohong...&Chen, Xiaoyuan.(2022).A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma.EJNMMI RESEARCH,12,(1)
MLA：
Wang, Guochang,et al."A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma".EJNMMI RESEARCH 12..1(2022)
